The ultrasound imaging technology developer backed by multiple corporates has completed a series C round that brought its overall funding to $320m.
Exo, a US-based ultrasound imaging system developer backed by corporates Applied Materials, GlaxoSmithKline, Intel, OSF HealthCare, Sony, TDK and Wanxiang, has secured $220m in a series C round.
RA Capital Management led the round, which also included contributions from BlackRock, Sands Capital, Avidity Partners and Pura Vida Investments, alongside unnamed existing investors.
Founded in 2015, Exo has developed a medical ultrasound device which uses nano-materials, artificial intelligence, sensor technologies, advanced signal processing and computation to deliver high image fidelity, quality,…
